Why we need easy access to all data from all clinical trials and how to accomplish it

International calls for registering all trials involving humans and for sharing the results, and sometimes also the raw data and the trial protocols, have increased in recent years. Such calls have come, for example, from the Organization for Economic Cooperation and Development (OECD), the World Health Organization (WHO), the US National Institutes of Heath, the US Congress, the European Commission, the European ombudsman, journal editors, The Cochrane Collaboration, and several funders, for example the UK Medical Research Council, the Wellcome Trust, the Bill and Melinda Gates Foundation and the Hewlett Foundation.Calls for data sharing have mostly been restricted to publicly-funded research, but I argue that the distinction between publicly-funded and industry-funded research is an artificial and irrelevant one, as the interests of the patients must override commercial interests.I also argue why it is a moral imperative to render all results from all trials involving humans, also healthy volunteers, publicly available. Respect for trial participants who often run a personal and unknown risk by participating in trials requires that they - and therefore also the society at large that they represent - be seen as the ultimate owners of trial data.Data sharing would lead to tremendous benefits for patients, progress in science, and rational use of healthcare resources based on evidence we can trust. The harmful consequences are minor compared to the benefits. It has been amply documented that the current situation, with selective reporting of favorable research and biased data analyses being the norm rather than the exception, is harmful to patients and has led to the death of tens of thousands of patients that could have been avoided.National and supranational legislation is needed to make data sharing happen as guidelines and other voluntary agreements do not work. I propose the contents of such legislation and of appropriate sanctions to hold accountable those who refuse to share their data.

[1]  Mark Walport,et al.  Sharing research data to improve public health , 2011, The Lancet.

[2]  Sally Hopewell,et al.  Publication bias in clinical trials due to statistical significance or direction of trial results. , 2009, The Cochrane database of systematic reviews.

[3]  A. Wertheimer,et al.  Why Patients Continue to Participate in Clinical Research , 2008 .

[4]  L. Stalley,et al.  The Influence of the Pharmaceutical Industry , 2004 .

[5]  Ray Moynihan Overdo$ed America: The Broken Promise of American Medicine , 2004, BMJ : British Medical Journal.

[6]  M. Egger,et al.  COX 2 inhibitors, traditional NSAIDs, and the heart , 2005, BMJ : British Medical Journal.

[7]  M. Hanefeld,et al.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial , 2009, The Lancet.

[8]  Silvio Garattini,et al.  Efficacy, safety, and cost of new anticancer drugs , 2002, BMJ : British Medical Journal.

[9]  Matthew J. Thompson,et al.  Ensuring safe and effective drugs: who can do what it takes? , 2011, BMJ : British Medical Journal.

[10]  Lethia Collins Rn Msn Cnor Cfnp Overdo$ed America: The Broken Promise of American Medicine , 2006 .

[11]  A. Hrõbjartsson,et al.  Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. , 2004, JAMA.

[12]  R Day,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.

[13]  C. Grady,et al.  Why patients continue to participate in clinical research. , 2008, Archives of internal medicine.

[14]  E. Topol,et al.  Risk of cardiovascular events associated with selective COX-2 inhibitors. , 2001, JAMA.

[15]  Douglas G Altman,et al.  Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols , 2008, BMJ : British Medical Journal.

[16]  H. Wulff,et al.  Rational diagnosis and treatment. , 1986, The Journal of medicine and philosophy.

[17]  N. Hadler Overtreated: Why Too Much Medicine Is Making Us Sicker and Poorer , 2007 .

[18]  R. Matthews Hooked: Ethics, the Medical Profession, and the Pharmaceutical Industry , 2008, Journal of Nuclear Medicine.

[19]  Eric J Topol,et al.  Failing the public health--rofecoxib, Merck, and the FDA. , 2004, The New England journal of medicine.

[20]  D. Cohen Rosiglitazone: what went wrong? , 2010, BMJ : British Medical Journal.

[21]  D. Eyding,et al.  Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials , 2010, BMJ : British Medical Journal.

[22]  J. Avorn Dangerous deception--hiding the evidence of adverse drug effects. , 2006, The New England journal of medicine.

[23]  D. Cohen Complications: tracking down the data on oseltamivir , 2009, BMJ : British Medical Journal.

[24]  R. DeRubeis,et al.  Antidepressant drug effects and depression severity: a patient-level meta-analysis. , 2010, JAMA.

[25]  D. Carr Wellcome Trust Policy on Data Management and Sharing , 2011 .

[26]  Merrill Goozner,et al.  The $800 Million Pill: The Truth behind the Cost of New Drugs , 2004 .

[27]  Lise,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.

[28]  A. Andreasen On the Take: How Medicine's Complicity with Big Business Can Endanger Your Health , 2005 .

[29]  W. Fitzgerald Corporate Crime in the Pharmaceutical industry , 1984 .

[30]  Richard M. Smith,et al.  Big publishers cut access to journals in poor countries , 2011, The Lancet.

[31]  D. Healy Did regulators fail over selective serotonin reuptake inhibitors? , 2006, BMJ : British Medical Journal.

[32]  G. Sweeney,et al.  Global corruption report , 2011 .

[33]  Lisa Bero,et al.  Factors Associated with Findings of Published Trials of Drug–Drug Comparisons: Why Some Statins Appear More Efficacious than Others , 2007, PLoS medicine.

[34]  P. Jesilow Prescription for profit , 1993 .

[35]  J Savulescu,et al.  Are research ethics committees behaving unethically? Some suggestions for improving performance and accountability , 1996, BMJ.

[36]  Alex Berenson,et al.  Evidence in Vioxx suits shows intervention by Merck officials. , 2005, The New York times on the Web.

[37]  F. Mosteller,et al.  A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. , 1992, JAMA.

[38]  J. Jureidini,et al.  Clinical trials and drug promotion: Selective reporting of study 329 , 2008 .

[39]  H. Chaiklin On the Take: How Medicine??s Complicity With Big Business Can Endanger Your Health , 2006 .

[40]  P. Gøtzsche,et al.  Opening up data at the European Medicines Agency , 2011, BMJ : British Medical Journal.

[41]  Trish Groves Managing UK research data for future use , 2009, BMJ : British Medical Journal.

[42]  B. Caldwell,et al.  Risk of Cardiovascular Events and Celecoxib: a Systematic Review and Meta-Analysis , 2006 .

[43]  P. Gøtzsche,et al.  Rational Diagnosis and Treatment: Evidence-Based Clinical Decision-Making , 2000 .

[44]  P. Glasziou,et al.  Avoidable waste in the production and reporting of research evidence , 2009, The Lancet.

[45]  L. Dopson,et al.  What Went Wrong? , 2007, Wollstonecraft.

[46]  Peter Rost,et al.  The Whistleblower: Confessions of a Healthcare Hitman , 2006 .

[47]  E. Topol,et al.  Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. , 2005, JAMA.

[48]  John Braithwaite,et al.  Corporate Crime in the Pharmaceutical Industry , 1984 .

[49]  S. Goldbeck-Wood Denmark takes a lead on research ethics , 1998, BMJ.

[50]  Kay Dickersin,et al.  Outcome reporting in industry-sponsored trials of gabapentin for off-label use. , 2009, The New England journal of medicine.

[51]  Jeanne Lenzer,et al.  FDA is incapable of protecting US “against another Vioxx” , 2004, BMJ : British Medical Journal.

[52]  D. Altman,et al.  Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers , 2010, BMJ : British Medical Journal.

[53]  L. Marsa Prescription for Profits : How the Pharmaceutical Industry Bankrolled the Unholy Marriage Between Science and Business , 1997 .

[54]  Jeffrey M Drazen,et al.  Expression of concern reaffirmed. , 2006, The New England journal of medicine.

[55]  S. Goodman,et al.  A Systematic Examination of the Citation of Prior Research in Reports of Randomized, Controlled Trials , 2011, Annals of Internal Medicine.

[56]  R. Temple,et al.  Drug-review deadlines and safety problems. , 2008, The New England journal of medicine.

[57]  T. Furukawa All clinical trials must be reported in detail and made publicly available , 2004, BMJ : British Medical Journal.

[58]  Other Communication from the Commission to the Council, the European Parliament, the European Economic and Social Committee and the Committee of the Regions: Annual Policy Strategy for 2008 , 2007 .

[59]  D. Rennie,et al.  Influences on the Quality of Published Drug Studies , 1996, International Journal of Technology Assessment in Health Care.

[60]  P. Gøtzsche,et al.  Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. , 1999, JAMA.

[61]  S. Shoor,et al.  Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study , 2005, The Lancet.

[62]  N. Scott,et al.  Outcome reporting bias and individual patient data meta-analysis: a case study in surgery , 2001 .

[63]  The truth about drug companies: how they deceive us and what to do about it , 2006 .

[64]  Nicki Panoskaltsis,et al.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. , 2006, The New England journal of medicine.

[65]  Brian Hutton,et al.  Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? , 2005, Clinical trials.

[66]  D. Safer DESIGN AND REPORTING MODIFICATIONS IN INDUSTRY-SPONSORED COMPARATIVE PSYCHOPHARMACOLOGY TRIALS , 2002, The Journal of nervous and mental disease.

[67]  R. Moynihan,et al.  Selling Sickness: How the World's Biggest Pharmaceutical Companies are Turning Us All into Patients , 2005 .

[68]  J. Kassirer On the Take , 2005 .

[69]  Douglas G Altman,et al.  Comparison of protocols and registry entries to published reports for randomised controlled trials. , 2011, The Cochrane database of systematic reviews.

[70]  J. Abramson Overdosed America: The Broken Promise of American Medicine , 2004 .

[71]  T. Cymet,et al.  The Truth about Drug Companies: How They Deceive Us and What to Do about It , 2006 .

[72]  B. Wieseler,et al.  Finding studies on reboxetine: a tale of hide and seek , 2010, BMJ : British Medical Journal.

[73]  R. Rosenthal,et al.  Selective publication of antidepressant trials and its influence on apparent efficacy. , 2008, The New England journal of medicine.

[74]  A. Hrõbjartsson,et al.  [Constraints on publication rights in industry-initiated clinical trials--secondary publication]. , 2006, Ugeskrift for laeger.

[75]  A. Skene,et al.  The effect of lorcainide on arrhythmias and survival in patients with acute myocardial infarction: an example of publication bias. , 1993, International journal of cardiology.

[76]  D. Altman,et al.  Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research , 2004, Canadian Medical Association Journal.

[77]  B. Beermann,et al.  Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications , 2003, BMJ : British Medical Journal.

[78]  Peter Jüni,et al.  Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? , 2002, BMJ : British Medical Journal.

[79]  Jerry Avorn,et al.  Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs , 2004 .

[80]  G. K. Chambers,et al.  Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. , 2001, JAMA.

[81]  H. Brody,et al.  Hooked: Ethics, the Medical Profession, and the Pharmaceutical Industry , 2006 .

[82]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[83]  Geoffrey C. Bowker,et al.  Promoting Access to Public Research Data for Scientific, Economic, and Social Development , 2004, Data Sci. J..

[84]  Richard Beasley,et al.  Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. , 2006, Journal of the Royal Society of Medicine.

[85]  M. Gordon Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412 , 2008 .

[86]  Michele Harms,et al.  Clinical trial registration. , 2011, Physiotherapy.

[87]  G. Pc Bias in double-blind trials. , 1990 .

[88]  Ana Marusic,et al.  Clinical trial registration: looking back and moving ahead , 2007, The Lancet.

[89]  M. Hanefeld,et al.  Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. , 2007, The New England journal of medicine.

[90]  A. Hrõbjartsson,et al.  Constraints on publication rights in industry-initiated clinical trials. , 2006, JAMA.

[91]  Jeffrey M Drazen,et al.  Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8. , 2005, The New England journal of medicine.

[92]  T. Pang,et al.  From Mexico to Mali: four years in the history of clinical trial registration , 2009, Journal of evidence-based medicine.

[93]  J. Avorn,et al.  Drug-review deadlines and safety problems. , 2008, The New England journal of medicine.

[94]  M. Angell The Truth About the Drug Companies: How They Deceive Us and What to Do About It , 2004 .

[95]  C. Deangelis,et al.  Ensuring integrity in industry-sponsored research: primum non nocere, revisited. , 2010, JAMA.

[96]  P. Gøtzsche Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. , 1989, Controlled clinical trials.

[97]  Bruce M. Psaty,et al.  Minimizing bias in randomized trials: the importance of blinding. , 2010, JAMA.

[98]  Karen Ekernas,et al.  Facemasks and Hand Hygiene to Prevent Influenza Transmission in Households: A Cluster Randomized Trial , 2010 .

[99]  G. Annas Globalized clinical trials and informed consent. , 2009, The New England journal of medicine.

[100]  L. Mcgoey,et al.  If NICE was in the USA , 2009, The Lancet.

[101]  S. Garattini Confidentiality , 2003, The Lancet.

[102]  J. Brophy Selling safety--lessons from muraglitazar. , 2005, JAMA.

[103]  J. Tanne Pfizer pays record fine for off-label promotion of four drugs , 2009, BMJ : British Medical Journal.

[104]  T. Chalmers,et al.  A survey of clinical trials of antibiotic prophylaxis in colon surgery: evidence against further use of no-treatment controls. , 1981, The New England journal of medicine.

[105]  D. Graham,et al.  More on advisory committee decision , 2010, BMJ : British Medical Journal.

[106]  A. Vickers,et al.  Empirical Study of Data Sharing by Authors Publishing in PLoS Journals , 2009, PloS one.

[107]  P. Lurie,et al.  Misleading data analyses in salmeterol (SMART) study , 2005, The Lancet.

[108]  J. Abraham Science, politics, and the pharmaceutical industry , 1995 .

[109]  B. Lewis What Went Wrong , 2001 .

[110]  Lisa Bero,et al.  Reporting Bias in Drug Trials Submitted to the Food and Drug Administration: Review of Publication and Presentation , 2008, PLoS medicine.

[111]  Hooman Momen Equitable access to scientific and technical information for health. , 2003, Bulletin of the World Health Organization.